ナノドラッグデリバリー技術：主要企業、製品および2015年までの展望

Abstract

This major strategic analysis provides a detailed insight into the current and future market for nano-enabled drug delivery technology.

Providing...

Critical analyses and competitive ratings for major specialist developers Unique sales forecasts to 2015 for key current and new products utilising nano-enabled drug delivery technologies A comprehensive examination of this major drug delivery sector

Nanotechnology, the application of functional materials, devices, and systems of matter in the sub-100 nanometre scale has the potential to improve the delivery of approved and novel drugs through the design of nano-engineered drugs and the development of a plethora of nano-carriers. Whilst the pharmaceutical industry has been slow to invest resources into this innovative technology, a number of nanotechnology-focused companies have become established and are driving the future of this rapidly evolving market.

Companies are adopting different strategies to improve the therapeutic potential, bioavailability, solubility and dosage of drugs through physical manipulation of therapeutic agents e.g. nanocrystals, nanoparticles and nanosuspensions as well as the targeted delivery of small molecule and large molecular drugs using a range of nano-carriers e.g. carbon/ceramic nanostructures, dendrimers, liposomes, micelles and polymer nanoparticles

Twelve nano-enabled products are now approved for the treatment of a range of conditions from antibacterial infections to cancer and from the central nervous system to metabolic disorders. These products utilise a range of nanotechnologies including liposomes and polymeric micelles and have been developed by a handful of companies. Together these products generated global sales of over US$2.3 billion in 2006 and are forecast to reach sales of over US$3 billion by 2009.

Competitive environment

The report identifies 22 companies which are evaluating nano-enabled products in pre-clinical or clinical development. Of these, seven companies are likely to have products that will reach the market by 2015.

A US$3.4 billion market in the making

By 2015, we forecast that nano-enabled products could generate sales in excess of US$3.4 billion driven by the uptake of innovative drug delivery systems including nanoparticle formulations, dendrimers and micelles and a new era of biocompatible nanoparticle coatings will begin to emerge that have applications in medical devices and dental implants. This is still very much an emerging market and we believe considerable commercial opportunities still exist for the pharma industry to form strategic alliances with nano-specialists and to tap into this powerful technology that may help to address the need for safer, more effective medicines.

Table of Contents

Executive Summary

• Competitor Ratio Analysis Summary

Introduction

Overview of nanotechnology: past, present & future

• Figure 1: Top ten applications of nanotechnology in developing countries
• Nanotechnology: motivators & resistors
  • Motivators
  • Resistors
• Nanotechnology: impact on product lifecycles

NANOTECHNOLOGY IN DRUG DELIVERY

• Core nanotechnology used by the pharma industry
  • Nano-engineered drugs
  • Nano-carriers
    • Figure 2: Dendrimer structure
    • Figure 3: Liposome structure
    • Figure 4: Micelle structure
• Current therapeutic application of nanotechnology in drug delivery
  • Leading brands that utilise nanotechnology delivery
    • Table 1: Nanotechnology-enabled approved drugs
• Future commercial applications & opportunities

STRATEGIES OF DRUG DELIVERY COMPANIES

• Leading nanotechnology drug delivery companies
  • Table 2: Leading nanotechnology-enabled drug delivery companies
• Partnerships & acquisitions
  • Strategic development & commercialisation partnerships and joint ventures
    • Table 3: Recent partnerships & acquisitions in the nanotechnology field
  • Mergers & acquisitions
    • Table 4: Nanotechnology patents

THE NANOTECHNOLOGY MARKET

• Now 2007
  • Table 5: Approved nano-enabled product sales
• Future 2015
  • Table 6: Novel nano-enabled product sales
  • Table 7: Global nano-enabled product sales

COMPETITOR ANALYSIS

• Movers & Shakers: Cutting edge or losing their grip
  • Table 8: Movers & shakers in nanotechnology drug delivery systems
• COMPANY PROFILES
  • Abraxis Bioscience
    • Table 9: Abraxis' product pipeline
    • Table 10: Abraxis Drug Delivery Sales
  • Access Pharmaceuticals
    • Table 11: Access Pharmaceuticals product pipeline
  • AlphaRx Corporation
    • Table 12: AlphaRx' product pipeline
    • Table 13: AlphaRx' pharmaceuticals drug delivery sales
  • ALZA Corporation
    • Table 14: ALZA' s drug delivery sales
  • BioSante Pharmaceuticals
    • Table 15: BioSante' s product pipeline
    • Table 16: BioSante' s drug delivery sales
  • Camurus AB
    • Table 17: Camurus AB' s product pipeline
    • Table 18: Camurus AB' s drug delivery sales
  • Eiffel Technologies
    • Table 19: Eiffel' s product pipeline
  • Elan Corporation
    • Table 20: Elan' s product pipeline
    • Table 21: Elan' s drug delivery sales
  • Eurand
    • Table 22: Eurand' s product pipeline
  • Gilead Sciences
    • Table 23: Gilead Sciences' product pipeline
    • Table 24: Gilead Sciences' drug delivery sales
  • Nano Interface Technology
    • Table 25: NITI' s product pipeline
  • Nano S Biotechnology GmbH
    • Table 26: Nano S' product pipeline
  • NanoBio Corporation
    • Table 27: NanoBio' s product pipeline
    • Table 28: NanoBio' s drug delivery sales
  • NanoBioMagnetics
    • Table 29: NanoBioMagnetics' product pipeline
  • Nanobiotix
    • Table 30: Nanobiotix' product pipeline
  • NanoCarrier
    • Table 31: NanoCarrier' s product pipeline
    • Table 32: NanoCarrier' s drug delivery sales
  • Nanotechnology Victoria, Ltd
    • Table 33: NanoVic' s product pipeline
  • NanoMaterials Technology
    • Table 34: NanoMaterial' s product pipeline
  • Nanotherapeutics
    • Table 35: Nanotherapeutics' product pipeline
    • Table 36: Nanotherapeutics' drug delivery sales
  • Novavax
    • Table 37: Novavax' s product pipeline
    • Table 38: Novavax' s drug delivery sales
  • SkyePharma
    • Table 39: SkyePharma' s product pipeline
    • Table 40: SkyePharma' s product sales
  • Spherics
    • Table 41: Spheric' s product pipeline

APENDIX 1

• Table 42: Global nanotechnology approved drugs sales 2006A-20015E

APENDIX 2

• Table 43: Global nanotechnology developmental drugs sales 2006A-20015E

APENDIX 3

• Competitor Ratio Analysis Criteria
  • Table 44: Key nanotechnology delivery companies by 2015

BIBLIOGRAPHY

GLOSSARY

ACRONYM S